Cognex's Strong Q2 Margins, Q3 Guidance Boost Shares, UBS Says

MT Newswires Live
08/01

Cognex (CGNX) posted its highest adjusted earnings before interest, taxes, depreciation, and amortization margin in two years during Q2, and Q3 guidance topped Wall Street estimates, UBS Securities said Wednesday in a note.

The company's shares jumped 21% in recent Thursday trading.

The 20.7% adjusted EBITDA margin reflected disciplined cost containment, and Q3 revenue and profit guidance "firmly above" consensus estimates contrasted with the outlook in previous quarters that trailed expectations, UBS said.

Additional growth catalysts include a new medical lab automation partnership, possible tax benefits and improving demand trends, the note said.

UBS has a buy rating on Cognex stock with a price target of $53.

Price: 40.75, Change: +6.99, Percent Change: +20.70

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10